蛋白质化疗药物复合物的制备

Hydrophobic chemotherapeutic drugs typically suffer from low solubility and short blood circulation time, which severely limit their clinical applications. Albumin has been used as an excellent carrier for drugs such as paclitaxel to enhance the efficacy of chemotherapeutic agents. In this study, doxorubicin (DOX) was selected as a representative chemotherapeutic drug to investigate the feasibility of using bovine serum albumin (BSA) as a carrier to improve its application performance. Albumin-DOX complex nanoparticles were prepared by physical encapsulation, and their particle size and zeta potential were characterized by dynamic light scattering (DLS). The encapsulation efficiency and drug loading capacity of the complexes were calculated to evaluate their basic properties as antitumor nanomedicines. The results showed that albumin-DOX complexes with a particle size of approximately 300 nm were successfully prepared. The complexes exhibited stable physical properties and definite drug-loading capacity. Their negatively charged surface and appropriate particle size are expected to optimize the in vivo distribution behavior of DOX and improve its bioavailability.